论文部分内容阅读
目的观察二甲双胍对T2DM早期糖尿病肾病(DN)的疗效。方法将118例T2DM并发早期DN的患者随机分为二甲双胍组和阿卡波糖组。两组分别在服用二甲双胍及阿卡波糖的基础上口服贝那普利片20mg/d,疗程24周。观察两组治疗前后的血压、血糖、HbA1c、稳态、模型胰岛素-抵抗指数(HOMA-IR)、高敏C反应蛋白(hsC-RP)、UAER的变化。结果二甲双胍组治疗前后的血压、血糖、HbA1c、HOMA-IR、hsC-RP、UAER的变化明显,差异有统计学意义。UAER治疗前(106.1±20.45)μg/min,治疗后(52.12±10.34)μg/min,(P<0.05);阿卡波糖组血压、hsC-RP、UAER治疗前后变化差异无统计学意义(P>0.05)。结论对于T2DM早期DN的患者,二甲双胍在降糖的同时,也能降低UAER。
Objective To observe the effect of metformin on early diabetic nephropathy (DN) in patients with T2DM. Methods A total of 118 T2DM patients with early DN were randomly divided into metformin group and acarbose group. Two groups were treated with metformin and acarbose based on oral benazepril tablets 20mg / d, treatment for 24 weeks. The changes of blood pressure, blood glucose, HbA1c, homeostasis, HOMA-IR, hsC-RP and UAER were observed before and after treatment. Results The changes of blood pressure, blood glucose, HbA1c, HOMA-IR, hsC-RP and UAER in metformin group before and after treatment were significantly different with statistical significance. There were no significant differences in blood pressure, hsC-RP and UAER before and after UAER treatment (106.1 ± 20.45 μg / min, 52.12 ± 10.34 μg / min after treatment (P <0.05) P> 0.05). Conclusion For patients with early stage T2DM, metformin may reduce UAER while lowering blood sugar.